On November 7, 2025 Trained Therapeutix Discovery, Inc., a biotech company training immunity at its origin with nanomedicines, reported preclinical data on RIDE-001, a nanomedicine designed to program myeloid progenitor cells for an anticancer innate immune response, were presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting. The data demonstrated that RIDE-001 effectively induced trained immunity in vitro in primary human immune cells, induced anti-tumor immunity in mouse tumor models of melanoma and colorectal cancer, and safely induced innate immune responses in rats and non-human primates. RIDE-001 showed therapeutic activity against solid tumors as a single agent, and it also exhibited synergy in combination with immune checkpoint inhibition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Myeloid cells can promote cancer by suppressing anti-tumor immune responses, enhancing tumor angiogenesis and facilitating metastasis, but due to their plasticity in the tumor microenvironment, they have been considered an unattractive therapeutic target," said Willem Mulder, PhD, Chief Scientific Officer of Trained Therapeutix Discovery. "Our approach with RIDE-001 is a breakthrough in immune-oncology, as it targets myeloid progenitor cells before they differentiate into immune cells. By programing myeloid cells at their naissance, we can deploy the power of the innate immune response against cancer. Based on these promising data demonstrating consistent myeloid cell training and antitumor activity across species, in addition to RIDE-001’s favorable safety profile, we have initiated GMP manufacturing in anticipation of the first clinical studies in patients with solid tumors."

RIDE-001 was developed using Trained Therapeutix Discovery’s proprietary ApoA1-based nanomedicines platform to target the bone marrow where it activates the intracellular pattern recognition receptor NOD2. This triggers epigenetic changes in myeloid progenitor cells, inducing the production of trained myeloid cells to generate durable, anti-tumor responses.

RIDE-001 preclinical data showed:

A dose-dependent rise in NOD2 activation;
Trained immunity as assessed by peripheral blood mononuclear cells (PBMCs);
Trained myeloid cells in rats demonstrating a shift in monocyte phenotype and increased blood neutrophil counts;
Trained myeloid cells in non-human primates with a consistent increase in intermediate monocytes in both males and females following each administered dose;
Single-agent anti-tumor efficacy in the highly immunosuppressive B16F10 melanoma mouse model;
Synergy with a subtherapeutic dose of anti-PD1 in the MC38 colorectal cancer mouse model;
And a favorable safety profile.
A copy of the poster titled "RIDE-001: A well-tolerated innate immunotherapy to treat cancer by targeting and reprogramming bone marrow progenitor cells" (abstract number 1178) is available on the company’s website.

(Press release, Trained Therapeutix Discovery, NOV 7, 2025, View Source [SID1234660997])